The Acromegaly Drug Market is expected to register a CAGR of 7.2% during the forecast period. Acromegaly is a hormonal condition that occurs when the pituitary gland produces too much growth hormone in maturity.

Bones develop in size, when you have too much growth hormone. This causes gigantism in children, which is defined as an increase in height. In adulthood, however, there is no variation in height. Instead, acromegaly refers to an increase in bone size that is limited to the bones of your hands, foot, and face. Hypertension, osteoarthritis, diabetes mellitus, goitre, and eyesight loss are some of the problems associated with acromegaly progression.

Acromegaly affects around 69,000 people globally and about 24,000 in the US, of whom an estimated 8,000 are treated chronically with somatostatin analogue injections. According to the National Institutes of Health (NIH), there are three to four new cases per million each year.

The rising Global Knowledge about hormonal problem, medication and therapies drives the market during the forecast  period.

The improvement in the patient's overall clinical status as a result of the treatment is a significant contributor to the market's growth.

An increase in the number of patients with this rare disease, particularly among the adult population, enhances demand for the drug, which is expected to fuel market expansion significantly during the forecast years.

Technological advancements and increased R&D expenditure from major manufacturers, in discovery of innovative goods are giving profitable chances, that will fuel market growth over the forecast years.

In March 2021, the US Food and Drug Administration (FDA) approved MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. 

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Regions Covered- Globally
• Competitive Landscape: Pfizer Inc, Novartis AG, Validus Pharmaceuticals LLC, Ipsen, Chiasma, Inc, Ionis Pharmaceuticals Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Acromegaly Drug Market by Product Type

• Somatostatin Analogs
• Growth Hormone Receptor Antagonist (GHRA)
• Dopamine Agonists
• Other Product Types 

Global Acromegaly Drug Market– Segment by Region